Risk Assessments - Key to a Viral Safety Management Plan

Instructor: Kathryn Martin Remington
Product ID: 701480
  • Duration: 47 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

This Viral Safety webinar training will discuss the testing used to generate data for risk assessment and train how to calculate viral risk.

Why should you Attend:

An inherent risk exists for biotechnology products derived from cell lines. To date these products have not been implicated in the transmission of viruses, but the risk is still present, and the clinical consequences of a contamination event are potentially very serious. Consequently, manufacturers are expected to provide a level of confidence that their product has a very low risk of virus transmission. This is done by preparing a risk assessment in which the risk of transmission of a known viral pathogen is calculated. The risk assessment incorporates data from three sources: 1) testing product source materials such as cell lines and raw materials for adventitious viruses, 2) verifying the absence of viral contaminants in process intermediates and 3) demonstrating the capacity of the manufacturing process to clear infectious viruses.

This presentation will explain the testing used to generate data used in the risk assessment and walk attendees through the calculations using several examples.Please have a scientific calculator handy and re-familiarize yourself with the "log" and "anti-log" (10x) functions.

Learning objectives :

  • How do I know if the viral clearance my process provides is enough?
  • Retrovirus or Retroviral like particles are present in my production cell line. How does this impact my downstream process?
  • How do I calculate viral risk?

Areas Covered in the seminar:

  • The viral testing required for source materials.
  • Determine if there is enough viral clearance for your process .
  • How the testing for adventitious viruses is related to viral clearance.
  • How to calculate a risk factor.
  • Which stage(s) of development require risk assessments.

Who will benefit:

This webinar will provide valuable assistance to all biopharmaceutical companies that produce biological products from cell lines. Companies that manufacture human- or animal-derived products will also find this information useful. The employees who will benefit include:

  • Process development scientists
  • QA managers and personnel
  • Regulatory personnel
  • Consultants

Instructor Profile:

Kathryn Martin Remington, Ph.D. is the Senior Manager of Virology at Catalent Pharma Solutions, in Research Triangle Park, North Carolina, a full-service solution provider to the pharmaceutical industry. She holds M.S. and Ph.D. degrees in Microbiology and has over 20 years of experience in virology. Before coming to industry, she worked in research studying drug resistant AIDS viruses. She was previously the Section Head of Viral Validation for Bayer HealthCare. Kathryn has been involved in the viral safety of biologics for over 12 years and is the author of number scientific publications on viral safety. She is a frequent speaker at conferences and workshops.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed